TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03153995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: soft tissue expansion
Description: Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue expansion
Description: Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months
Study: NCT02748928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power
Description: Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
Study: NCT02481245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: 30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
Study: NCT04669119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01379677

Intervention type: DRUG
Group type: OTHER
Intervention: Rubidium-82
Description: Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use

Intervention type: DRUG
Group type: OTHER
Intervention: Sestamibi. reconstitution with sodium pertechnetate (99mTc)
Description: Maximum dose allowed per injection: 1000 MBq Intravenous Use
Study: NCT02427412

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline water
Description: 30 ml of Saline water injected into the knee capsula at the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
Study: NCT02347527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Implicit Priming
Description: A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Implicit Priming
Description: A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Implicit Priming
Description: A 10-minute implicit priming intervention, associating food images with images of neutral valence.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Implicit Priming
Description: A 10-minute implicit priming intervention, associating food images with images of neutral valence.
Study: NCT02687841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120and pentoxyphylline (PTX)
Description: AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxyphylline (PTX)
Description: pentoxyphylline 400mg QD PO x 10 days.
Study: NCT03677271

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Study: NCT00298506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multitherapy
Description: Tacrolimus,4mg/d, MMF 1.0g/d
Study: NCT03788109

Intervention type: PROCEDURE
Group type: OTHER
Intervention: device: combined solid state HRiM
Description: The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
Study: NCT03688048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light treatment lamp
Description: Exposure to bright white light (1 hour, 10 000 lux)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham negative ion generator
Description: Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
Study: NCT03883373

Intervention type: PROCEDURE
Intervention: alveolar bone graft with cancellous bone and a cortical block
Description: alveolar bone graft with cancellous bone only

Intervention type: PROCEDURE
Intervention: alveolar bone graft with cancellous bone only
Description: alveolar bone graft with cancellous bone only
Study: NCT01657773

Intervention type: OTHER
Intervention: Ultrasound examination and Colonoscopy examination

Intervention type: OTHER
Intervention: Ultrasound examination and Colonoscopy examination
Study: NCT03439319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyndMove®
Description: This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
Study: NCT03310047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion, Lidocaine, 0.5%, 5 mL
Description: A catheter-based perineural infusion of 5 mL Lidocaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion, Lidocaine, 0.5%, 5 mL
Description: A catheter-based perineural infusion of 5 mL Lidocaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion, Lidocaine, 0.5%, 10 mL
Description: A catheter-based perineural infusion of 10 mL Lidocaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion, Lidocaine, 0.5%, 10 mL
Description: A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
Study: NCT05475509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtually reality
Description: Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
Study: NCT00521495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium permanent magnet
Description: 3/4 diameter by 1/8 thick permanent magnet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium magnet
Description: A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium magnet
Description: A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neodymium magnet
Description: A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnet
Description: 0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
Study: NCT04115813

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project YES! Youth Engaging for Success
Description: Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project YES! Youth Engaging for Success
Description: Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
Study: NCT04057092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement INergy-FLD
Description: INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
Study: NCT01144832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ebastine
Description: 20 milligram capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: one capsule once daily
Study: NCT02318264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Elastic tape placed over the skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Elastic tape placed over the skin
Study: NCT03873532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
Study: NCT02936765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with prosthetic disc replacement / ESP.
Description: Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy with prosthetic disc replacement / Squale.
Description: Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
Study: NCT02993276

Intervention type: DEVICE
Intervention: Neurocap®
Description: NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
Study: NCT04479046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PMMA crowns
Description: New type of pediatric crowns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PMMA crowns
Description: New type of pediatric crowns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PMMA crowns
Description: New type of pediatric crowns
Study: NCT01843296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
Study: NCT00667537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 chloride (Xofigo®, BAY88-8223) injection
Description: Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
Study: NCT01199952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment group: receives counseling phone call intervention
Description: Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
Study: NCT01488175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no tourniquet
Description: a tourniquet around the thigh is not used during insertion of the TKA
Study: NCT01843296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT02276807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation
Description: This is a 4-session individual workshop using behavioral activation techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
Study: NCT04376931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Solution
Description: Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
Study: NCT02361606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An Internet Cognitive-Behavioral Intervention
Description: We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
Study: NCT02460146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CXA-10 placebo
Description: The placebo contains olive oil with BHT (0.08% to 0.10%).
Study: NCT04533373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIEP Flap Neurotization
Description: We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall.
Study: NCT01819805

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
Study: NCT03901742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein-enriched nutrition
Description: Protein-enriched enteral nutrition with a polymeric infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Protein-enriched Nutrition
Description: High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enteral Nutrition
Description: Cow's milk based infant formula.
Study: NCT01679756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right hemicolectomy for cancer
Description: After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy for cancer
Description: After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
Study: NCT03273933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragONE
Description: The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DragONE
Description: The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartOne
Description: A little portable spirometer connected to DragONE allows daily PEF monitoring.
Study: NCT03037242

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transtibial pullout technique
Description: Evaluating radographs
Study: NCT03316053

Intervention type: OTHER
Intervention: Tissue sample for genetic testing
Description: Tissue sample to be obtained during routine endoscopy
Study: NCT04312113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived, autologous mesenchymal stem cells
Description: Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
Study: NCT04205513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medly
Description: Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
Study: NCT03907072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201 (suvodirsen)
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201 (suvodirsen)
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffered saline solution
Study: NCT04168775

Intervention type: DEVICE
Group type: OTHER
Intervention: Home PIFR monitoring with InCheck Dial
Description: The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
Study: NCT01176422

Intervention type: GENETIC
Intervention: Blood sample
Description: Blood samples will be collected before and after treatment completion.
Study: NCT04531436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief mindful eating intervention
Description: Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
Study: NCT04659356

Intervention type: OTHER
Intervention: Patients admitted in Intensive Care Units
Description: Data will be collected computerized patient records by the clinicians in charge of the patient.